Importantly, TM also suppressed S6 phosphorylation in non-BRAF mutated melanoma cell lines indicating a broader therapeutic potential of TM in patients without the BRAF mutation but where the PI3K/Akt/mTOR pathway is activated such as in patients harboring NRAS mutations [48]. This evidence concerns the gene NRAS and melanoma.